Intelgenx Technologs (IGXT) 0.6410 $IGXT IntelGenx

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Intelgenx Technologs (IGXT) 0.6410 $IGXT

IntelGenx Reports Second Quarter 2016 Financial Results and Appointment of New Director
Marketwire Canada - Thu Aug 11, 3:01PM CDT
SAINT-LAURENT, QUEBEC--(Marketwired - Aug 11, 2016) - IntelGenx Technologies Corp. (TSX VENTURE:IGX)(OTCQX:IGXT) (the "Company" or "IntelGenx" today reported its second quarter 2016 financial results for the three-month and six-month periods ended June 30, 2016. All amounts are in U.S. Dollars unless otherwise stated. The Company will host a conference call today at 4:30 p.m. ET to provide a corporate update.
IGX.VN: 0.860 (-0.040)

IntelGenx Announces Sale of Forfivo XL(R) Royalty for $6 Million
Marketwire Canada - Fri Aug 05, 3:01PM CDT
SAINT-LAURENT, CANADA--(Marketwired - Aug 5, 2016) - IntelGenx Corp., (TSX VENTURE:IGX)(OTCQX:IGXT), (the "Company" or "IntelGenx" today announced that it has sold its royalty on future sales of Forfivo XL® to SWK Holdings Corporation (SWKH.OB) ("SWK" or the "Company" for $6 million (CAD$8 million). Forfivo XL® (Bupropion extended-release) is the first 450 mg bupropion HCl tablet indicated for Major Depressive Disorder, approved by the FDA.
IGX.VN: 0.860 (-0.040)

IntelGenx to Report Second Quarter 2016 Financial Results on August 11, 2016
Marketwired - Tue Aug 02, 8:18AM CDT
SAINT-LAURENT, CANADA--(Marketwired - Aug 2, 2016) - IntelGenx Technologies Corp., (TSX VENTURE:IGX)(OTCQX:IGXT), today announced that it will release its second quarter 2016 results for the period ended June 30, 2016, on August 11, 2016 at the close of the financial markets.
IGX.VN: 0.860 (-0.040)

IntelGenx Reports Amendment of Stock Option Plan
Marketwire Canada - Thu May 12, 3:01PM CDT
SAINT LAURENT, QUEBEC--(Marketwired - May 12, 2016) - IntelGenx Technologies Corp. (TSX VENTURE:IGX)(OTCQX:IGXT) (the "Company" or "IntelGenx" reported today, that the Company's Board of Directors approved to amend the 2006 Stock Option Plan and to redesignate it as the "2016 Stock Option Plan". The number of shares available for issuance under the new Plan increased by 1,331,233 from 5,030,292 to 6,361,525, or 10% of the Company's issued and outstanding shares as of May 10, 2016. The 2016 Stock Option Plan is available on EDGAR and SEDAR for a complete review of the amendments.
IGX.VN: 0.860 (-0.040)

IntelGenx Reports First Quarter 2016 Financial Results
Marketwire Canada - Tue May 10, 3:01PM CDT
SAINT LAURENT, QUEBEC--(Marketwired - May 10, 2016) - IntelGenx Corp. (TSX VENTURE:IGX)(OTCQX:IGXT) (the "Company" or "IntelGenx" today reported its first quarter 2016 financial results for the three-month period ended March 31, 2016. All amounts are in U.S. Dollars unless otherwise stated. The Company will host a conference call to provide a corporate update on Thursday, May 12th at 9:00 a.m. ET. Details of the conference call and webcast are listed below in this release.
IGX.VN: 0.860 (-0.040)

IntelGenx to Report First Quarter 2016 Financial Results on May 10, 2016
Marketwired - Thu May 05, 5:01PM CDT
SAINT LAURENT, QUEBEC--(Marketwired - May 5, 2016) - IntelGenx Technologies Corp. (TSX VENTURE:IGX)(OTCQX:IGXT) ("IntelGenx", today announced that it will release its first quarter 2016 financial results on May 10, 2016 at 4:00 p.m. ET followed by the annual general meeting of shareholders. A special presentation will then be made by Dr. Ludwig Aigner on "Rejuvenation of the aged brain - an example of drug delivery in drug repurposing." Shareholders are then invited to the company's grand opening of its brand new state-of-the-art manufacturing facilities where tours will be offered.
IGX.VN: 0.860 (-0.040)

IntelGenx and RedHill Biopharma Announce RIZAPORT(TM) Commercialization Term Sheet With Grupo Juste for Spain and Additional Potential Territories
Marketwired - Tue Mar 29, 6:01AM CDT
IntelGenx Corp. (TSX VENTURE: IGX)(OTCQX: IGXT) and RedHill Biopharma Ltd. (NASDAQ: RDHL)(TASE: RDHL) today announced the binding term sheet agreement with Grupo Juste S.A.Q.F for the commercialization of RIZAPORT(TM), a unique oral thin film for the treatment of acute migraines in the country of Spain. The definitive agreement plans to be signed within 60 days of the execution of the binding term sheet. Financial terms of the agreement were not disclosed.
RDHL: 15.69 (+0.17), IGX.VN: 0.860 (-0.040)

RedHill Biopharma and IntelGenx Announce RIZAPORT(TM) Commercialization Term Sheet with Grupo JUSTE for Spain and Additional Potential Territories
GlobeNewswire - Tue Mar 29, 6:00AM CDT
-- RedHill and its co-development partner, IntelGenx Corp., have entered into a binding term sheet with Grupo JUSTE granting an exclusive license to commercialize their acute migraine drug RIZAPORTin Spain, and a right of first refusal for additional territories
RDHL: 15.69 (+0.17), IGX.VN: 0.860 (-0.040)

IntelGenx Announces Development and Commercialization Term Sheet with a Global Pharmaceutical Company for Up to Three Products
Marketwired - Thu Mar 24, 11:05AM CDT
IntelGenx Corp., (TSX VENTURE: IGX)(OTCQX: IGXT), today announced the signing of a term sheet with a global pharmaceutical company for the development and commercialization of up to three products utilizing IntelGenx' proprietary VersaFilm(TM) technology. Pursuant to the term sheet, IntelGenx granted an exclusive negotiation period during which time the parties will conduct diligence and work towards entry into a definitive agreement. IntelGenx receives $100,000 at the time of signing the term sheet, in consideration for granting an exclusive negotiation right. If entered into, IntelGenx expects the definitive agreement to be finalized by the second quarter of 2016.
IGX.VN: 0.860 (-0.040)

IntelGenx to Host Conference Call and Webcast of Fourth Quarter and Full-Year 2015 Financial Results on Wednesday, March 23
Marketwired - Wed Mar 09, 7:31AM CST
IntelGenx Technologies Corp. (TSX VENTURE: IGX)(OTCQX: IGXT) ("IntelGenx", today announced that it will release its fourth quarter and full-year 2015 financial results on March 22, 2016 at the close of the financial markets.
IGX.VN: 0.860 (-0.040)

IntelGenx Files Loxapine Oral Film Patent for Schizophrenia
Marketwired - Wed Feb 10, 7:31AM CST
IntelGenx Corp., (TSX VENTURE: IGX)(OTCQX: IGXT), today announced that it has submitted a patent application with the US patent office for an oral film dosage form containing Loxapine for the treatment of anxiety and aggression in patients suffering from schizophrenia or bipolar 1 disorder.
IGX.VN: 0.860 (-0.040)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 212

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 245

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 375

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 213

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
Human Frontier Mission Puts AI Research on Display

Updated Category News Views 238

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 262

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 377

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 301

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 192

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 417

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading

Top 5 Most Recently Viewed Articles

APT Miner Mobile App Revolutionizes Cloud Mining Experience

Updated Category News Views 352

APT Miner Mobile App: A New Era in Cryptocurrency Mining APT Miner has launched a groundbreaking mobile application that opens the door to easy cryptocurrency mining for everyone. With this new app, users can seamlessly engage in mining operations from their mobile devices, without the need for technical expertise or complicated setups. The platform caters to a wide range...

Continue Reading
Investors Urged to Act Before September Deadline in Alto Case

Updated Category News Views 233

Important Announcement for Alto Neuroscience Investors In a recent advisory, investors of Alto Neuroscience, Inc. (NYSE: ANRO) are being urged to secure legal counsel as the deadline for a pivotal class action lawsuit approaches. The deadline for lead plaintiffs to step forward is September 19, 2025, providing investors who are affected by a range of factors related to...

Continue Reading
Strategic Sale: McStarlite Co. Partners with Standex International

Updated Category News Views 244

Strategic Changes Ahead for McStarlite Co. In a significant move, Janes Capital Partners has announced its role as the exclusive advisor for McStarlite Co. in its acquisition by Standex International Corporation (NYSE:SXI). This partnership highlights Janes Capital Partners’ capability to navigate complex transactions in the aerospace sector. McStarlite Co.: A Leader in...

Continue Reading
Codis Accelerates Growth with 1315 Capital Investment

Updated Category News Views 185

Codis Secures Funding for Expansion Codis, a leading contract development and manufacturing organization (CDMO) specializing in spray drying and related technologies, is excited to announce a significant growth investment from 1315 Capital. This partnership aims to bolster Codis's manufacturing capabilities significantly, particularly at its Haverhill facility in the UK....

Continue Reading
A Decade of Growth: The Journey of an Investment in Guidewire

Updated Category News Views 174

The Growth Journey of Guidewire Software Guidewire Software (GWRE) has seen significant advancements in the last decade, marking an impressive annualized return of 17.03%. Over this period, it has outperformed the broader market by 4.38%, which speaks volumes about the company’s stability and growth potential. Understanding Guidewire’s Market Position With a current...

Continue Reading